Academic Journal
Quartile not availableDrugs in R&D
About Drugs in R&D
Drugs in R&D is a peer-reviewed scholarly journal published by Adis, Springer Healthcare (NZ). It focuses on Pharmacogenetics and Drug Metabolism, Pharmaceutical studies and practices, Pharmacovigilance and Adverse Drug Reactions.
Key indicators: ISSN 11745886, 11796901; H-index 62; 1,368 works indexed; 20,285 citations.
Scope and Subject Areas
The journal covers: Pharmacogenetics and Drug Metabolism, Pharmaceutical studies and practices, Pharmacovigilance and Adverse Drug Reactions, Statistical Methods in Clinical Trials, Antibiotics Pharmacokinetics and Efficacy, Biosimilars and Bioanalytical Methods, Analytical Methods in Pharmaceuticals, Diabetes Treatment and Management.
Journal Metrics
- H-index (62): 62 articles have each received at least 62 citations.
- Works indexed: 1,368 publications tracked in OpenAlex.
- Total citations: 20,285.
- Open Access: Yes.
Publishing in Drugs in R&D
Researchers should verify the journal's current scope, submission guidelines, and indexing status via the official journal website before submitting. Ensure your manuscript aligns with the journal's subject areas.
Official website: https://link.springer.com/journal/40268
Frequently Asked Questions
What is the ISSN of Drugs in R&D?
11745886, 11796901.
What subjects does Drugs in R&D cover?
Pharmacogenetics and Drug Metabolism, Pharmaceutical studies and practices, Pharmacovigilance and Adverse Drug Reactions, Statistical Methods in Clinical Trials, Antibiotics Pharmacokinetics and Efficacy.
Who publishes Drugs in R&D?
Adis, Springer Healthcare.
Is Drugs in R&D peer-reviewed?
Yes — it is a peer-reviewed scholarly journal.
Journal Metrics
A quartile may vary by subject category. Values without a source or reporting year are unverified historical entries. Verify the current Journal Impact Factor with Clarivate or the publisher before using it.
Aims & Scope
The publisher’s official aims and scope have not yet been verified for this profile. Use the journal website to check subject fit and accepted article types before submitting.
Recent Research Articles
Latest publications matched automatically by ISSN.
Anti-Fungal and Toxicology Assessment of ISFP10, an Inhibitor of Fungal Phosphoglucomutase (PGM)
Madeline R. Pellegrino, Marc Bindzus, Theodore J. Kottom, Savita Ayyalasomayajula et al.
2026-09-26 · DOI: 10.1007/s40268-026-00551-yComparative Pharmacokinetics of Trientine Dihydrochloride Capsules: A Randomized, Open-Label, Reference-Controlled, Two-Period Crossover Study in Healthy Volunteers
Christian J. Hartmann, Frank Tacke, Isabelle Mohr, Michael Praktiknjo et al.
2026-09-09 · DOI: 10.1007/s40268-026-00553-wStudy on the Pharmacokinetics and Pharmacodynamics of Transdermal Estradiol Gel Administered Repeatedly in Postmenopausal Women
Jouni Sirviö, Tuula Ahtola-Sätilä, Merja Kirjavainen, Paula Rytilä et al.
2026-09-09 · DOI: 10.1007/s40268-026-00552-xOptimizing Drug-Resistant Epilepsy Management: Cenobamate’s role in the Surgery/Neuromodulation Pathway
Giancarlo Di Gennaro, Paolo Bonanni, Francesco Deleo, Antonio Gambardella et al.
2026-06 · DOI: 10.1007/s40268-026-00548-7Development and Optimization of a Biphasic-Release Acetazolamide Tablet-in-Tablet Formulation
Si-kai Wang, Wei Li, Miao-miao Guo, Man Han et al.
2026-06 · DOI: 10.1007/s40268-026-00546-9Gabapentin Extended Release Tablets in Healthy Subjects Under Fed Conditions: A Randomized, Open-Label, Two-Treatment, Two-Period, Two-Sequence, Single Dose, Crossover, Comparative Bioavailability Study
Sudershan Kumar, Arshad Khuroo, Sanjay Jagannath Gurule, Sachin Mehra et al.
2026-06 · DOI: 10.1007/s40268-026-00547-8A Combination of the Tryptophan Hydroxylase Inhibitor Telotristat with the mTOR Inhibitor Everolimus as an Effective Strategy Against Neuroendocrine Tumors
Javier Molina-Cerrillo, Arantzazu Sierra-Ramirez, José L. López-Aceituno, Marinela Méndez-Pertuz et al.
2026-06 · DOI: 10.1007/s40268-026-00544-xUstekinumab in the Management of Perianal Fistulizing Crohn’s Disease: Current Evidence and Practical Strategies
Bolin Yang
2026-06 · DOI: 10.1007/s40268-026-00545-wResponse to “Treatment Outcomes with Lanadelumab Every Two Weeks and Garadacimab Are Very Similar in Patients with Hereditary Angioedema”
Imtiaz A. Samjoo
2026-03 · DOI: 10.1007/s40268-026-00536-xThe Influence of Renal or Hepatic Impairment on the Pharmacokinetics of Iclepertin (BI 425809): Results from Two Phase I Open-Label, Non-randomised, Single Dose, Parallel Design Studies
HeeJae Choi, Shilpa Madari, Elmar Daalman, Brett A. English et al.
2026-03 · DOI: 10.1007/s40268-026-00537-wArylpiperazine Derivative NAF19 Inhibits Prostate Cancer Activity and Its Molecular Mechanisms
Hua Jiang, Mingzhen Xu, Songsong Jiang, Weiqiang Huang et al.
2026-03 · DOI: 10.1007/s40268-026-00542-zTreatment Outcomes with Lanadelumab Every 2 Weeks and Garadacimab are Very Similar in Patients with Hereditary Angioedema
Irmgard Andresen, Natalie Khutoryansky, Sarah L. Feeny, Alissa Dangel et al.
2026-03 · DOI: 10.1007/s40268-026-00539-8Advanced Drug Delivery Strategies for Overcoming Biological Barriers: Tumor Microenvironment and Blood–Brain Barrier
Yicong Lei, Tingyu Xiao, Xin Hu, Huaqing Lin et al.
2026-03 · DOI: 10.1007/s40268-026-00538-9Updated Viloxazine Pharmacology: Experiments Establish Norepinephrine Transporter Occupancy and Serotonin 5-HT2C, 5-HT2B, and 5-HT7 Receptor Binding at Therapeutically Relevant Concentrations
Jennie Garcia-Olivares, Brittney Yegla, Jennifer Koch, Chungping Yu et al.
2026-03 · DOI: 10.1007/s40268-026-00543-yPharmacokinetics and Bioequivalence Evaluation of Piracetam Tablet: A Randomized, Single-Dose, Two-Period, Crossover Study in Healthy Chinese Participants Under Fasting and Fed Conditions
Hegui Yan, Ming Zhou, Zhixiang Pan, Yu Peng et al.
2026-03 · DOI: 10.1007/s40268-026-00541-0Development and Evaluation of Multiple-Unit Tablets for the Controlled Release of Lornoxicam
Yang Liu, Qiong-zhi Shi, Yanchen Wang, Ze-chun Long et al.
2026-03 · DOI: 10.1007/s40268-026-00540-1HIF-1α siRNA Enhances the Efficacy of Erlotinib in Non-small Cell Lung Cancer: A Novel Strategy to Reverse Hypoxia-Induced Drug Resistance
Haojie Jiang, Shunhui Cai, Xiaojun Zhang, Shijie Chen et al.
2026-03 · DOI: 10.1007/s40268-025-00534-5Preclinical Evaluation of AHT-102, a CLDN18.2 × CD3 Bispecific Antibody: Pharmacokinetics, Anti-Tumor Efficacy, Tissue Distribution, and Safety Profile
Huilun Chu, Guili Xu, Yunlong Liu, Niliang Qian et al.
2026-03 · DOI: 10.1007/s40268-026-00535-yMultiple-Dose Up-Titration Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Omecamtiv Mecarbil in Healthy Chinese Subjects
Xuening Li, Hui Li, Hongrong Xu, Fei Yuan et al.
2025-12 · DOI: 10.1007/s40268-025-00532-7Safety, Tolerability and Pharmacokinetics of a High-Dose, Rapid-Infusion Monoclonal Antibody: Phase I Results for Intravenous Sotrovimab 3000 mg
Yasmin Sánchez-Pearson, Jennifer Moore, Jerzy Daniluk, Sookti Bhangu et al.
2025-12 · DOI: 10.1007/s40268-025-00530-9Reviews
Community Reviews
Version History
October 10, 2026 at 3:36 am
October 9, 2026